Neo Kuma Ventures's guest appearances

Neo Kuma Ventures

The Pulse by Wharton Digital Health

Hurdle Health

Andrew Parker

Andrew Dudum

Andreessen Horowitz

Afton Vechery

Chris Altchek

Paul Martino

Stephen Smith

Jon Bloom

Kristina Saffran

Andrew Hines

Steve Kraus

Vijay Patel

Nancy Brown

Halle Tecco

OwlTail

Clara Burtenshaw

In this episode, we sat down with Clara Burtenshaw, Partner and Investor at Neo Kuma Ventures. We discussed: -The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development -The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders -Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network -Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space

In this episode, we sat down with <a href="https://www.linkedin.com/in/clara-burtenshaw-5b184aa7/" rel="noopener nofollow" target="_blank">Clara Burtenshaw</a>, Partner and Investor at <a href="https://www.neokuma.co/" rel="noopener nofollow" target="_blank">Neo Kuma Ventures</a>. We discussed: -The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development -The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders -Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network -Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space

Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication

In this episode, we sat down with Clara Burtenshaw, Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience.We discussed:-The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development-The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders-Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network-Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space

In this episode, we sat down with Clara Burtenshaw, Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience. We discussed: -The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development -The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders -Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network -Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space